Kirkland & Ellis, still among the league table leaders in deal value and volume amidst a down year for mergers and acquisitions and for the firm's practice in that area, got a nice shot in the arm to start Q4 as the firm represented Bristol Myers Squibb (BMS) in its $13.1 billion acquisition of fellow pharmaceutical company MyoKardia on Monday. The latter was represented by Goodwin Procter.